Business Wire

Online Download Starts on 24th December 2020 for Nintendo Switch: Dreadfully Difficult Game, but Somehow, Nostalgic “Nosferatu Lilinor”

18.12.2020 12:00:00 EET | Business Wire | Press release

Share

Hiyori Inc. (from Taito-ku, Tokyo, with Representative Director : Igarashi Takahiro), will release its first Online Puzzle Action game “Nosferatu Lilinor,” under the publishing brand “neon®”, for Nintendo Switch™ as a downloadable on Thursday, 24 December 2020, with additional features and improvements over its currently available Steam® version.

What is Nosferatu Lilinor?

A Retro-style, stage-by-stage, action-puzzle game. You will play as a vampire girl named “Lilinor” and lead her to the goal by solving puzzles with dreadfully high difficulty which will require timing as well as route planning. Challenging it will be, and death will be more common than expected.

Pack-full, new additional features!

As per requests by fans of the Steam® version, the following new features for the Nintendo Switch™ version have been added.

  • The new, even-more-lenient ‘Very Easy’ mode. Most suitable for practicing.
  • More cute and unique skins.
  • Mid-stage alternative routes have been added, thus providing more choices for progression.
  • Update some Graphics. World Map added.
  • Zasha, the servant wolf, will be available to play in 2P mode to provide assistance to Lilinor.

Adjust the gameplay to your heart desires with these addition new features, new stages and new skins. Have fun!

Game Information

  • Title: Nosferatu Lilinor
  • Genre: High difficulty action-puzzle games
  • Copyright: ©2019-2020 neon
  • Released Date: Thursday, 24 December 2020
  • Supporting Language: English, Chinese (Simplified Chinese/Traditional Chinese), Japanese, Korean, Spanish, German, French
  • Price: € 14,53
  • Pre-order discount: Yes (16, December 2020 00:00 (CET) - 23, December 2020 23:59 (CET))
  • Playable Players: 2 Players per hardware
  • Suitable age : All ages (rating ages rank A by Cero)
                          IARC_USK 6
                          IARC_PEGI 3+
                          IARC_OFLCC(AGCB) G (General)
                          IARC_OFLC.NZ G (General)
  • Platform: Nintendo Switch™ (For download only)
  • Official Webpage’s URL: http://hiyori-prd.com/lilinorsw/
  • Official Twitter’s URL: https://twitter.com/NLilinorE/

“The image as you see is from the Development stage”

Company Information

Product’s Brand : Hiyori Inc.
Representative Director : Igarashi Takahiro
Address : 601 Kyou Wa no.1 Building, East Taito 1-29-4, Taito-Ku, Tokyo, JAPAN, 110-0016
Established : 20 January 2015
Business details : Entertainment software planning, Developing, Sale
URL : http://hiyori-prd.com/

[Press materials – Download]

https://www.hiyori-prd.com/lilinorsw/dl/neon_Press-specific_graphic_materials201216.rar

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Games Contact Information
Hiyori Inc. User Support
neon_support@hiyori-prd.com

Request for Press release
Hiyori Inc. User Support
Contact: Takahiro Igarashi
Phone: +81-90-9853-3940
E-Mail: neon_support@hiyori-prd.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye